Genetic polymorphisms associated with heart failure: A literature review

Journal of International Medical Research

Volumn 44, Issue 1, 2016, Pages 15-29

  Guo, Mengqi ^a   Guo, Guanlun ^b   Ji, Xiaoping ^a  

^a SHANDONG UNIVERSITY   (China)

^b WUHAN UNIVERSITY OF TECHNOLOGY   (China)

Author keywords

genetic polymorphism; Heart failure; prognosis; susceptibility; therapy

Indexed keywords

ALPHA 2C ADRENERGIC RECEPTOR; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSINOGEN; BETA 1 ADRENERGIC RECEPTOR; BETA 2 ADRENERGIC RECEPTOR; CYTOCHROME P450 2D6; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; ENDOTHELIN 1; G PROTEIN COUPLED RECEPTOR KINASE; HEAT SHOCK PROTEIN 27; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 4; MANGANESE SUPEROXIDE DISMUTASE; MICRORNA; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN;

ADRENERGIC SYSTEM; ELECTRONIC MEDICAL RECORD; GENE INTERACTION; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; INFLAMMATION; PHENOTYPE; PROGNOSIS; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; RNA SEQUENCE; SYSTEMATIC REVIEW; TREATMENT RESPONSE; EPISTASIS; GENETIC ASSOCIATION STUDY; GENETIC PREDISPOSITION; GENETICS; SINGLE NUCLEOTIDE POLYMORPHISM;

EPISTASIS, GENETIC; GENETIC ASSOCIATION STUDIES; GENETIC PREDISPOSITION TO DISEASE; HEART FAILURE; HUMANS; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS;

EID: 84958692903     PISSN: 03000605     EISSN: 14732300     Source Type: Journal    
DOI: 10.1177/0300060515604755     Document Type: Review

References (117)

1. G.S.BleuminkA.M.KnetschM.C.Sturkenboom. Quantifying the heart failure epidemic: prevalence, incidence rate, lifetime risk and prognosis of heart failure the Rotterdam study. Eur Heart J2004; 25: 1614–1619.
2. D.W.KitzmanW.C.LittleP.H.Brubaker. Pathophysiological characterization of isolated diastolic heart failure in comparison to systolic heart failure. JAMA2002; 288: 2144–2150.
3. J.J.McMurrayM.A.Pfeffer. Heart failure. Lancet2005; 365: 1877–1889.
4. A.MuthumalaF.DrenosP.M.Elliott. Role of beta adrenergic receptor polymorphisms in heart failure: systematic review and meta-analysis. Eur J Heart Fail2008; 10: 3–13.
5. S.N.ChangJ.W.LinJ.M.Juang. Association between genetic polymorphisms in the renin-angiotensin system and systolic heart failure revised by a propensity score-based analysis. Cardiology2010; 116: 279–285.
6. A.D.TiagoD.BadenhorstD.Skudicky. An aldosterone synthase gene variant is associated with improvement in left ventricular ejection fraction in dilated cardiomyopathy. Cardiovasc Res2002; 54: 584–589.
7. T.AkbulutT.BilselS.Terzi. Relationship between ACE gene polymorphism and ischemic chronic heart failure in Turkish population. Eur J Med Res2003; 8: 247–253.
8. L.CovoloU.GelattiM.Metra. Angiotensin-converting-enzyme gene polymorphism and heart failure: a case-control study. Biomarkers2003; 8: 429–436.
9. W.HuangC.XieH.Zhou. Association of the angiotensin-converting enzyme gene polymorphism with chronic heart failure in Chinese Han patients. Eur J Heart Fail2004; 6: 23–27.
10. M.Zakrzewski-JakubiakS.de DenusM.P.Dube. Ten renin-angiotensin system-related gene polymorphisms in maximally treated Canadian Caucasian patients with heart failure. Br J Clin Pharmacol2008; 65: 742–751.
11. R.E.AmirO.AmirH.Paz. Genotype-phenotype associations between chymase and angiotensin-converting enzyme gene polymorphisms in chronic systolic heart failure patients. Genet Med2008; 10: 593–598.
12. T.S.RaiP.S.DhandapanyT.S.Ahluwalia. ACE I/D polymorphism in Indian patients with hypertrophic cardiomyopathy and dilated cardiomyopathy. Mol Cell Biochem2008; 311: 67–72.
13. C.K.WuC.T.TsaiJ.J.Hwang. Renin-angiotensin system gene polymorphisms and diastolic heart failure. Eur J Clin Invest2008; 38: 789–797.
14. B.KucukarabaciA.BirdaneH.V.Gunes. Association between angiotensin converting enzyme (ACE) gene I/D polymorphism frequency and plasma ACE concentration in patients with idiopathic dilated cardiomyopathy. Anadolu Kardiyol Derg2008; 8: 65–66.
15. L.TiretC.MalletO.Poirier. Lack of association between polymorphisms of eight candidate genes and idiopathic dilated cardiomyopathy: the CARDIGENE study. J Am Coll Cardiol2000; 35: 29–35.
16. Y.BaiL.WangS.Hu. Association of angiotensin-converting enzyme I/D polymorphism with heart failure: a meta-analysis. Mol Cell Biochem2012; 361: 297–304.
17. A.MishraA.SrivastavaT.Mittal. Genetic predisposition to left ventricular dysfunction: a multigenic and multi-analytical approach. Gene2014; 546: 309–317.
18. O.AmirR.E.AmirH.Paz. Relation between AT1R gene polymorphism and long-term outcome in patients with heart failure. Cardiology2009; 112: 151–157.
19. O.E.BroddeH.BruckK.Leineweber. Cardiac adrenoceptors: physiological and pathophysiological relevance. J Pharmacol Sci2006; 100: 323–337.
20. A.J.SzentmiklosiN.SzentandrassyB.Hegyi. Chemistry, physiology, and pharmacology of β-adrenergic mechanisms in the heart. Why are beta-blocker antiarrhythmics superior?Curr Pharm Des2015; 21: 1030–1041.
21. W.N.LiuK.L.FuH.Y.Gao. β1 adrenergic receptor polymorphisms and heart failure: a meta-analysis on susceptibility, response to β-blocker therapy and prognosis. PLoS One2012; 7: e37659–e37659.
22. O.E.BroddeM.C.Michel. Adrenergic and muscarinic receptors in the human heart. Pharmacol Rev1999; 51: 651–690.
23. C.ForleoS.SorrentinoP.Guida. Beta1- and beta2-adrenergic receptor polymorphisms affect susceptibility to idiopathic dilated cardiomyopathy. J Cardiovasc Med (Hagerstown)2007; 8: 589–595.
24. K.LeineweberG.TenderichC.Wolf. Is there a role of the Thr164Ile-beta(2)-adrenoceptor polymorphism for the outcome of chronic heart failure?Basic Res Cardiol2006; 101: 479–484.
25. L.CovoloU.GelattiM.Metra. Role of beta1- and beta2-adrenoceptor polymorphisms in heart failure: a case-control study. Eur Heart J2004; 25: 1534–1541.
26. A.PaczkowskaM.SzperlL.Malek. Polymorphisms of the beta-1 and beta-2 adrenergic receptors in polish patients with idiopathic dilated cardiomyopathy. Kardiol Pol2009; 67: 235–241.
27. L.WangL.LuF.Zhang. Polymorphisms of beta-adrenoceptor and natriuretic peptide receptor genes influence the susceptibility to and the severity of idiopathic dilated cardiomyopathy in a Chinese cohort. J Card Fail2010; 16: 36–44.
28. K.M.SmallL.E.WagonerA.M.Levin. Synergistic polymorphisms of beta1- and alpha2C-adrenergic receptors and the risk of congestive heart failure. N Engl J Med2002; 347: 1135–1142.
29. S.NonenH.OkamotoM.Akino. No positive association between adrenergic receptor variants of alpha2cDel322, 325, beta1Ser49, beta1Arg389 and the risk for heart failure in the Japanese population. Br J Clin Pharmacol2005; 60: 414–417.
30. L.GullestadT.UelandL.E.Vinge. Inflammatory cytokines in heart failure: mediators and markers. Cardiology2012; 122: 23–35.
31. H.TakanoH.HasegawaT.Nagai. Implication of cardiac remodeling in heart failure: mechanisms and therapeutic strategies. Intern Med2003; 42: 465–469.
32. R.LuoX.LiX.Fan. Association of tumor necrosis factor-alpha gene G-308A polymorphism with dilated cardiomyopathy: a meta-analysis. DNA Cell Biol2013; 32: 130–137.
33. V.RuppertT.MeyerC.Struwe. Evidence for CTLA4 as a susceptibility gene for dilated cardiomyopathy. Eur J Hum Genet2010; 18: 694–699.
34. Q.LiY.GuoW.Tan. Cardioprotection afforded by inducible nitric oxide synthase gene therapy is mediated by cyclooxygenase-2 via a nuclear factor-kappaB dependent pathway. Circulation2007; 116: 1577–1584.
35. S.WuR.YinR.Ernest. Liver X receptors are negative regulators of cardiac hypertrophy via suppressing NF-kappaB signalling. Cardiovasc Res2009; 84: 119–126.
36. T.HamidS.Z.GuoJ.R.Kingery. Cardiomyocyte NF-kappaB p65 promotes adverse remodelling, apoptosis, and endoplasmic reticulum stress in heart failure. Cardiovasc Res2011; 89: 129–138.
37. D.SorrientoG.SantulliA.Fusco. Intracardiac injection of AdGRK5-NT reduces left ventricular hypertrophy by inhibiting NF-kappaB-dependent hypertrophic gene expression. Hypertension2010; 56: 696–704.
38. B.ZhouL.RaoY.Peng. Functional polymorphism of the NFKB1 gene promoter is related to the risk of dilated cardiomyopathy. BMC Med Genet2009; 10: 47–47.
39. D.G.SantosM.F.ResendeJ.G.Mill. Nuclear Factor (NF) kappaB polymorphism is associated with heart function in patients with heart failure. BMC Med Genet2010; 11: 89–89.
40. M.J.MahmoudiM.HedayatM.Taghvaei. Association of interleukin-4 gene polymorphisms with ischemic heart failure. Cardiol J2014; 21: 24–28.
41. P.CharronF.TessonO.Poirier. Identification of a genetic risk factor for idiopathic dilated cardiomyopathy, Involvement of a polymorphism in the endothelin receptor type a gene. CARDIGENE group. Eur Heart J1999; 20: 1587–1591.
42. M.G.ColomboE.CiofiniU.Paradossi. ET-1 Lys198Asn and ET(A) receptor H323H polymorphisms in heart failure. A case-control study. Cardiology2006; 105: 246–252.
43. M.BryR.KivelaV.M.Leppanen. Vascular endothelial growth factor-B in physiology and disease. Physiol Rev2014; 94: 779–794.
44. R.A.De BoerY.M.PintoD.J.Van Veldhuisen. The imbalance between oxygen demand and supply as a potential mechanism in the pathophysiology of heart failure: the role of microvascular growth and abnormalities. Microcirculation2003; 10: 113–126.
45. P.DouvarasD.G.AntonatosK.Kekou. Association of VEGF gene polymorphisms with the development of heart failure in patients after myocardial infarction. Cardiology2009; 114: 11–18.
46. L.SpinelliV.TrimarcoS.Di Marino. L41Q polymorphism of the G protein coupled receptor kinase 5 is associated with left ventricular apical ballooning syndrome. Eur J Heart Fail2010; 12: 13–16.
47. G.A.FigtreeR.D.BagnallI.Abdulla. No association of G-protein-coupled receptor kinase 5 or β-adrenergic receptor polymorphisms with Takotsubo cardiomyopathy in a large Australian cohort. Eur J Heart Fail2013; 15: 730–733.
48. A.MatsumoriT.YamadaH.Suzuki. Increased circulating cytokines in patients with myocarditis and cardiomyopathy. Br Heart J1994; 72: 561–566.
49. R.M.LebovitzH.ZhangH.Vogel. Neurodegeneration, myocardial injury, and perinatal death in mitochondrial superoxide dismutase-deficient mice. Proc Natl Acad Sci U S A1996; 93: 9782–9787.
50. S.Shimoda-MatsubayashiT.HattoriH.Matsumine. Mn SOD activity and protein in a patient with chromosome 6-linked autosomal recessive parkinsonism in comparison with Parkinson’s disease and control. Neurology1997; 49: 1257–1262.
51. S.HiroiH.HaradaH.Nishi. Polymorphisms in the SOD2 and HLA-DRB1 genes are associated with nonfamilial idiopathic dilated cardiomyopathy in Japanese. Biochem Biophys Res Commun1999; 261: 332–339.
52. A.VaskuM.GoldbergovaL.I.Holla. Two MMP-2 promoter polymorphisms (−790T/G and −735C/T) in chronic heart failure. Clin Chem Lab Med2003; 41: 1299–1303.
53. Y.HuaL.SongN.Wu. Polymorphisms of MMP-2 gene are associated with systolic heart failure risk in Han Chinese. Am J Med Sci2009; 337: 344–348.
54. K.StarkU.B.EsslingerW.Reinhard. Genetic association study identifies HSPB7 as a risk gene for idiopathic dilated cardiomyopathy. PLoS Genet2010; 6: e1001167–e1001167.
55. T.P.CappolaM.LiJ.He. Common variants in HSPB7 and FRMD4B associated with advanced heart failure. Circ Cardiovasc Genet2010; 3: 147–154.
56. G.W.Dorn2ndS.J.MatkovichW.H.Eschenbacher. A human 3’ miR-499 mutation alters cardiac mRNA targeting and function. Circ Res2012; 110: 958–967.
57. A.R.HarperB.M.MayosiA.Rodriguez. Common variation neighbouring micro-RNA 22 is associated with increased left ventricular mass. PLoS One2013; 8: e55061–e55061.
58. K.CurilaL.BenesovaP.Tomasov. Variants in miRNA regulating cardiac growth are not a common cause of hypertrophic cardiomyopathy. Cardiology2015; 130: 137–142.
59. D.M.McNamaraR.HolubkovL.Postava. Pharmacogenetic interactions between angiotensin-converting enzyme inhibitor therapy and the angiotensin-converting enzyme deletion polymorphism in patients with congestive heart failure. J Am Coll Cardiol2004; 44: 2019–2026.
60. M.A.CuocoA.C.PereiraF.Mota Gde. Genetic polymorphism, medical therapy and sequential cardiac function in patients with heart failure. Arq Bras Cardiol2008; 90: 252–256. [in Portuguese, English Abstract].
61. P.de GrooteN.HelbecqueN.Lamblin. Beta-adrenergic receptor blockade and the angiotensin-converting enzyme deletion polymorphism in patients with chronic heart failure. Eur J Heart Fail2004; 6: 17–21.
62. M.CicoiraA.RossiS.Bonapace. Effects of ACE gene insertion/deletion polymorphism on response to spironolactone in patients with chronic heart failure. Am J Med2004; 116: 657–661.
63. Y.MagnussonM.C.LevinR.Eggertsen. Ser49Gly of beta1-adrenergic receptor is associated with effective beta-blocker dose in dilated cardiomyopathy. Clin Pharmacol Ther2005; 78: 221–231.
64. M.BorjessonY.MagnussonA.Hjalmarson. A novel polymorphism in the gene coding for the beta(1)-adrenergic receptor associated with survival in patients with heart failure. Eur Heart J2000; 21: 1853–1858.
65. M.C.LevinS.MarulloO.Muntaner. The myocardium-protective Gly-49 variant of the beta 1-adrenergic receptor exhibits constitutive activity and increased desensitization and down-regulation. J Biol Chem2002; 277: 30429–30435.
66. D.A.RathzK.M.BrownL.A.Kramer. Amino acid 49 polymorphisms of the human beta1-adrenergic receptor affect agonist-promoted trafficking. J Cardiovasc Pharmacol2002; 39: 155–160.
67. M.MetraL.CovoloN.Pezzali. Role of beta-adrenergic receptor gene polymorphisms in the long-term effects of beta-blockade with carvedilol in patients with chronic heart failure. Cardiovasc Drugs Ther2010; 24: 49–60.
68. D.M.KayeB.SmirkC.Williams. Beta-adrenoceptor genotype influences the response to carvedilol in patients with congestive heart failure. Pharmacogenetics2003; 13: 379–382.
69. P.de GrooteN.HelbecqueN.Lamblin. Association between beta-1 and beta-2 adrenergic receptor gene polymorphisms and the response to beta-blockade in patients with stable congestive heart failure. Pharmacogenet Genomics2005; 15: 137–142.
70. M.D.LittlejohnB.R.PalmerA.M.Richards. Ile164 variant of beta2-adrenoceptor does not influence outcome in heart failure but may interact with beta blocker treatment. Eur J Heart Fail2008; 10: 55–59.
71. M.R.BristowG.A.MurphyH.Krause-Steinrauf. An alpha2C-adrenergic receptor polymorphism alters the norepinephrine-lowering effects and therapeutic response of the beta-blocker bucindolol in chronic heart failure. Circ Heart Fail2010; 3: 21–28.
72. S.KangX.HongC.W.Ruan. Effects of GRK5 and ADRB1 polymorphisms influence on systolic heart failure. J Transl Med2015; 13: 44–44.
73. S.B.LiggettS.CresciR.J.Kelly. A GRK5 polymorphism that inhibits beta-adrenergic receptor signaling is protective in heart failure. Nat Med2008; 14: 510–517.
74. S.RaimundoJ.FischerM.Eichelbaum. Elucidation of the genetic basis of the common ‘intermediate metabolizer’ phenotype for drug oxidation by CYP2D6. Pharmacogenetics2000; 10: 577–581.
75. U.M.ZangerJ.FischerS.Raimundo. Comprehensive analysis of the genetic factors determining expression and function of hepatic CYP2D6. Pharmacogenetics2001; 11: 573–585.
76. L.M.BaudhuinW.L.MillerL.Train. Relation of ADRB1, CYP2D6, and UGT1A1 polymorphisms with dose of, and response to, carvedilol or metoprolol therapy in patients with chronic heart failure. Am J Cardiol2010; 106: 402–408.
77. C.F.SharpS.J.GardinerB.P.Jensen. CYP2D6 genotype and its relationship with metoprolol dose, concentrations and effect in patients with systolic heart failure. Pharmacogenomics J2009; 9: 175–184.
78. T.RauR.HeideK.Bergmann. Effect of the CYP2D6 genotype on metoprolol metabolism persists during long-term treatment. Pharmacogenetics2002; 12: 465–472.
79. B.R.PalmerA.P.PilbrowT.G.Yandle. Angiotensin-converting enzyme gene polymorphism interacts with left ventricular ejection fraction and brain natriuretic peptide levels to predict mortality after myocardial infarction. J Am Coll Cardiol2003; 41: 729–736.
80. M.A.CuocoA.C.PereiraH.F.de Freitas. Angiotensin-converting enzyme gene deletion polymorphism modulation of onset of symptoms and survival rate of patients with heart failure. Int J Cardiol2005; 99: 97–103.
81. AlbuquerqueFNBrandao AASilva DA. Angiotensin-converting enzyme genetic polymorphism: its impact on cardiac remodeling. Arq Bras Cardiol2014; 102: 70–79.
82. C.K.WuJ.L.LuoC.T.Tsai. Demonstrating the pharmacogenetic effects of angiotensin-converting enzyme inhibitors on long-term prognosis of diastolic heart failure. Pharmacogenomics J2010; 10: 46–53.
83. S.CresciR.J.KellyT.P.Cappola. Clinical and genetic modifiers of long-term survival in heart failure. J Am Coll Cardiol2009; 54: 432–444.
84. A.BioloN.ClausellK.G.Santos. Impact of beta1-adrenergic receptor polymorphisms on susceptibility to heart failure, arrhythmogenesis, prognosis, and response to beta-blocker therapy. Am J Cardiol2008; 102: 726–732.
85. M.FiuzatM.L.NeelyA.Z.Starr. Association between adrenergic receptor genotypes and beta-blocker dose in heart failure patients: analysis from the HF-ACTION DNA substudy. Eur J Heart Fail2013; 15: 258–266.
86. C.ForleoN.RestaS.Sorrentino. Association of beta-adrenergic receptor polymorphisms and progression to heart failure in patients with idiopathic dilated cardiomyopathy. Am J Med2004; 117: 451–458.
87. K.LeineweberU.H.FreyG.Tenderich. The Arg16Gly-β(2)-adrenoceptor single nucleotide polymorphism: exercise capacity and survival in patients with end-stage heart failure. Naunyn Schmiedebergs Arch Pharmacol2010; 382: 357–365.
88. P.de GrooteN.LamblinN.Helbecque. The impact of beta-adrenoreceptor gene polymorphisms on survival in patients with congestive heart failure. Eur J Heart Fail2005; 7: 966–973.
89. S.B.LiggettL.E.WagonerL.L.Craft. The Ile164 beta2-adrenergic receptor polymorphism adversely affects the outcome of congestive heart failure. J Clin Invest1998; 102: 1534–1539.
90. E.BarbatoM.PenickaL.Delrue. Thr164Ile polymorphism of beta2-adrenergic receptor negatively modulates cardiac contractility: implications for prognosis in patients with idiopathic dilated cardiomyopathy. Heart2007; 93: 856–861.
91. O.AmirY.SmithB.Zafrir. Absence of the α(2c)-adrenoceptor Del322-325 allele is associated with increased mortality in patients with chronic systolic heart failure. J Card Fail2012; 18: 925–929.
92. C.F.McTiernanR.RamaniB.Burkhead. The methionine 196 arginine polymorphism of the TNF receptor 2 gene (TNFRSF1B) is not associated with worse outcomes in heart failure. Cytokine2012; 60: 838–842.
93. D.S.LiuX.O.LiB.W.Ying. Effects of single nucleotide polymorphisms 869 T/C and 915 G/C in the exon 1 locus of transforming growth factor-beta1 gene on chronic obstructive pulmonary disease susceptibility in Chinese. Chin Med J (Engl)2010; 123: 390–394.
94. K.A.WaschkeA.C.VillaniS.Vermeire. Tumor necrosis factor receptor gene polymorphisms in Crohn’s disease: association with clinical phenotypes. Am J Gastroenterol2005; 100: 1126–1133.
95. S.AdamopoulosF.KolokathisA.Gkouziouta. Cytokine gene polymorphisms are associated with markers of disease severity and prognosis in patients with idiopathic dilated cardiomyopathy. Cytokine2011; 54: 68–73.
96. P.van der MeerR.A.De BoerH.L.White. The VEGF +405 CC promoter polymorphism is associated with an impaired prognosis in patients with chronic heart failure: a MERIT-HF substudy. J Card Fail2005; 11: 279–284.
97. S.HerrmannK.Schmidt-PetersenJ.Pfeifer. A polymorphism in the endothelin-A receptor gene predicts survival in patients with idiopathic dilated cardiomyopathy. Eur Heart J2001; 22: 1948–1953.
98. CarnicerRCrabtreeMJSivakumaranV. Nitric oxide synthases in heart failure. Antioxid Redox Signal2013; 18: 1078–1099.
99. D.M.McNamaraR.HolubkovL.Postava. Effect of the Asp298 variant of endothelial nitric oxide synthase on survival for patients with congestive heart failure. Circulation2003; 107: 1598–1602.
100. G.MaiolinoG.P.Rossi. Effect of the Asp298 variant of endothelial nitric oxide synthase on survival for patients with congestive heart failure. Circulation2003; 108: e112–e112. ; author reply e112.
101. T.MorisakiM.GrossH.Morisaki. Molecular basis of AMP deaminase deficiency in skeletal muscle. Proc Natl Acad Sci U S A1992; 89: 6457–6461.
102. A.GastmannH.H.SiguschA.Henke. Role of adenosine monophosphate deaminase-1 gene polymorphism in patients with congestive heart failure (influence on tumor necrosis factor-alpha level and outcome). Am J Cardiol2004; 93: 1260–1264.
103. P.de GrooteN.LamblinN.Helbecque. The impact of the AMPD1 gene polymorphism on exercise capacity, other prognostic parameters, and survival in patients with stable congestive heart failure: a study in 686 consecutive patients. Am Heart J2006; 152: 736–741.
104. R.P.CollinsB.R.PalmerA.P.Pilbrow. Evaluation of AMPD1 C34T genotype as a predictor of mortality in heart failure and post-myocardial infarction patients. Am Heart J2006; 152: 312–320.
105. M.J.KolekJ.F.CarlquistS.Thaneemit-Chen. The role of a common adenosine monophosphate deaminase (AMPD)-1 polymorphism in outcomes of ischemic and nonischemic heart failure. J Card Fail2005; 11: 677–683.
106. F.VillarrealS.ZimmermannL.Makhsudova. Modulation of cardiac remodeling by adenosine: in vitro and in vivo effects. Mol Cell Biochem2003; 251: 17–26.
107. B.NormanR.L.SabinaE.Jansson. Regulation of skeletal muscle ATP catabolism by AMPD1 genotype during sprint exercise in asymptomatic subjects. J Appl Physiol (1985)2001; 91: 258–264.
108. Y.HuaL.SongN.Wu. Polymorphisms of MMP-2 gene are associated with systolic heart failure prognosis. Clin Chim Acta2009; 404: 119–123.
109. F.Mizon-GerardP.de GrooteN.Lamblin. Prognostic impact of matrix metalloproteinase gene polymorphisms in patients with heart failure according to the aetiology of left ventricular systolic dysfunction. Eur Heart J2004; 25: 688–693.
110. A.M.BennetM.C.van MaarleJ.Hallqvist. Association of TNF-alpha serum levels and TNFA promoter polymorphisms with risk of myocardial infarction. Atherosclerosis2006; 187: 408–414.
111. S.J.MatkovichD.J.Van BoovenA.Hindes. Cardiac signaling genes exhibit unexpected sequence diversity in sporadic cardiomyopathy, revealing HSPB7 polymorphisms associated with disease. J Clin Invest2010; 120: 280–289.
112. C.M.O’ConnorM.FiuzatP.E.Carson. Combinatorial pharmacogenetic interactions of bucindolol and β1, α2C adrenergic receptor polymorphisms. PloS one2012; 7: e44324–e44324.
113. M.R.TaylorD.SlavovK.Humphrey. Pharmacogenetic effect of an endothelin-1 haplotype on response to bucindolol therapy in chronic heart failure. Pharmacogenet Genomics2009; 19: 35–43.
114. B.AnderssonI.BlangeC.Sylvén. Angiotensin-II type 1 receptor gene polymorphism and long-term survival in patients with idiopathic congestive heart failure. Eur J Heart Fail1999; 1: 363–369.
115. A.OgimotoH.OkayamaT.Nagai. Impact of synergistic polymorphisms in adrenergic receptor-related genes and cardiovascular events in patients with dilated cardiomyopathy. Circ J2012; 76: 2003–2008.
116. A.BioloR.SalvaroN.Clausell. Impact of beta-2 Thr164Ile and combined beta-adrenergic receptor polymorphisms on prognosis in a cohort of heart failure outpatients. Braz J Med Biol Res2010; 43: 565–571.
117. J.ShinM.T.LobmeyerY.Gong. Relation of beta(2)-adrenoceptor haplotype to risk of death and heart transplantation in patients with heart failure. Am J Cardiol2007; 99: 250–255.